ZA201403575B - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Google Patents

Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Info

Publication number
ZA201403575B
ZA201403575B ZA2014/03575A ZA201403575A ZA201403575B ZA 201403575 B ZA201403575 B ZA 201403575B ZA 2014/03575 A ZA2014/03575 A ZA 2014/03575A ZA 201403575 A ZA201403575 A ZA 201403575A ZA 201403575 B ZA201403575 B ZA 201403575B
Authority
ZA
South Africa
Prior art keywords
halofenate
urate
gout
patients
methods
Prior art date
Application number
ZA2014/03575A
Other languages
English (en)
Inventor
A Mcwherter Charles
K Roberts Brian
chandra saha Gopal
Edward Lavan Brian
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of ZA201403575B publication Critical patent/ZA201403575B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2014/03575A 2011-11-04 2014-05-16 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent ZA201403575B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Publications (1)

Publication Number Publication Date
ZA201403575B true ZA201403575B (en) 2015-11-25

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/03575A ZA201403575B (en) 2011-11-04 2014-05-16 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Country Status (13)

Country Link
EP (1) EP2773336A4 (enrdf_load_stackoverflow)
JP (1) JP6202633B2 (enrdf_load_stackoverflow)
KR (1) KR20140121383A (enrdf_load_stackoverflow)
CN (2) CN109908124A (enrdf_load_stackoverflow)
AU (1) AU2011380507B2 (enrdf_load_stackoverflow)
CA (1) CA2859686C (enrdf_load_stackoverflow)
CL (1) CL2014001155A1 (enrdf_load_stackoverflow)
IL (1) IL232386A0 (enrdf_load_stackoverflow)
MX (1) MX357507B (enrdf_load_stackoverflow)
NZ (1) NZ624708A (enrdf_load_stackoverflow)
SG (1) SG11201402032RA (enrdf_load_stackoverflow)
WO (1) WO2013066349A1 (enrdf_load_stackoverflow)
ZA (1) ZA201403575B (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物
WO2021186250A2 (en) * 2020-03-15 2021-09-23 Allen Davidoff Methods of treating viral infections and health consequences

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US9023856B2 (en) * 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent

Also Published As

Publication number Publication date
CA2859686A1 (en) 2013-05-10
CA2859686C (en) 2018-09-11
CN109908124A (zh) 2019-06-21
EP2773336A4 (en) 2015-06-03
JP6202633B2 (ja) 2017-09-27
MX357507B (es) 2018-07-12
WO2013066349A1 (en) 2013-05-10
AU2011380507A1 (en) 2014-05-29
EP2773336A1 (en) 2014-09-10
JP2014532758A (ja) 2014-12-08
CN104066427A (zh) 2014-09-24
IL232386A0 (en) 2014-06-30
SG11201402032RA (en) 2014-09-26
CL2014001155A1 (es) 2015-01-16
AU2011380507B2 (en) 2017-06-15
KR20140121383A (ko) 2014-10-15
NZ624708A (en) 2015-11-27
MX2014005400A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
EP2716669A4 (en) METHOD OF MODIFYING SURFACE AND ELASTIC BODY HAVING MODIFIED SURFACE
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
EP2714172C0 (en) DEPLOYMENT MECHANISM FOR BODY VESSEL INSERTION DEVICES
EP2788075A4 (en) DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT
SG11201401811WA (en) Method for preventing and/or treating insulin resistance
AP2013007249A0 (en) Benzothiazole compounds and their pharmaceutical use
ZA201300055B (en) Treatment of gout and hyperuricemia
PT2663864T (pt) Método de avaliação de imunodiversidade e seu uso
DK2750705T3 (en) Methods for effectively and rapidly desensitizing allergic patients
EP2739352A4 (en) MULTIMODAL ELECTROTHERAPY PROCESS AND DEVICE
ZA201307742B (en) Method for manufacturing and utilizing ferritic-austenitic stainless steel
FI20115893L (fi) Menetelmä retention säätämiseksi ja menetelmässä käytettävä välituote
ZA201403575B (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
HUE047419T2 (hu) Tetrahidrokannabinol-11-sav savak alkalmazása fibrotikus betegségek kezelésében
EP2682248A4 (en) INJECTION-FORMED BODY AND METHOD OF MANUFACTURING THE SAME
PL2413718T3 (pl) Zastosowanie kwasu arachidonowego do zmniejszenia ryzyka insulinooporności w późniejszym życiu
SG11201401272RA (en) Method for manufacturing acrylic acid-based polymer and use for same
PT2630475T (pt) Método de diagnóstico e tratamento
SG11201406495UA (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
EP2863602A4 (en) ENGINEER AND METHOD FOR CORRECTING SQUARE ERRORS
IL232385A (en) Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder
EP2640376A4 (en) CAFFEINE ACID DERIVATIVES AND THEIR USE FOR IMPROVING NEURONAL CELL-LIFECITY
EP2773261A4 (en) PRESSURE GAUGE FOR TESTING THE SPINAL REGION AND METHOD THEREOF
SG10201609202PA (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
ZA201404738B (en) Treatment of type i and type ii diabetes